Ongoing studies of Ra-223–based combinations

An expert discusses other ongoing investigations exploring radium-223-based combinations for the treatment of metastatic castration-resistant prostate cancer, highlighting key studies and their potential impact on clinical practice.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Case presentation: Patient with metastatic CRPC after ARPI and docetaxel for localized PC

EP: 2.Therapeutic options for a patient with mCRPC after ADT + docetaxel

EP: 3.PEACE-3 study of enzalutamide + Ra-223 for ARPI-naïve mCRPC: Design and objectives

EP: 4.PEACE-3 Study Results: Study Population & Disposition

EP: 5.PEACE-3 Study Results: Efficacy

EP: 6.PEACE-3 Study Results: Safety

EP: 7.How would therapeutic options change if this patient was asymptomatic?

EP: 8.Protecting bone health for patients receiving Ra-223 + ARPI combination

Now Viewing

EP: 9.Ongoing studies of Ra-223–based combinations

EP: 10.Ongoing studies of Ra- 223–based combinations

What are some other ongoing investigations looking at Ra-223-based combinations?

Recent Videos

Case 3 (cont.): Management of Treatment-Associated ILD/Pneumonitis

Management of ADC-Related AEs

Current Practices and Initial Treatment Considerations for Patients With cGVHD

DLBCL Subtype Response Patterns: Optimizing Treatment Selection

Evolving Treatment Strategies in DLBCL: Real-World Clinical Experience

The Evolving Role of Lenvatinib in the HCC Therapeutic Landscape

Second-Line Therapy in Advanced HCC: Treatment Considerations and Evolving Options

HER2-Mutated NSCLC: Second-Line Treatment Selection and Emerging Approaches

HER2 Mutations in NSCLC

Treatment Implementation and Long-Term Considerations in BPDCN